Menu Search
Equities

BioCryst Pharmaceuticals Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
BO1:FRA

BioCryst Pharmaceuticals Inc

Actions
  • Price (EUR)5.18
  • Today's Change-0.168 / -3.14%
  • Shares traded2.00
  • 1 Year change-37.40%
  • Beta0.8018
Data delayed at least 15 minutes, as of Feb 06 2026 07:11 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. The RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older. Its portfolio also includes navenibart, which is a late-stage, long-acting plasma kallikrein inhibitor. It has also obtained an early-stage program for atopic dermatitis, STAR0310.

  • Revenue in USD (TTM)599.82m
  • Net income in USD-8.78m
  • Incorporated1991
  • Employees580.00
  • Location
    BioCryst Pharmaceuticals Inc4505 Emperor Blvd Ste 200DURHAM 27703-8457United StatesUSA
  • Phone+1 (302) 636-5400
  • Fax+1 (302) 636-5454
  • Websitehttps://www.biocryst.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		BCRX:NSQ since
announced		Transaction
value
Astria Therapeutics IncDeal completed14 Oct 202514 Oct 2025Deal completed-9.38%716.93m
Data delayed at least 15 minutes, as of Feb 06 2026 21:00 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.